Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01 B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy: e0004423

Background A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both to reduce the morbidity caused by this parasite and as a key component in efforts to eradicate malaria worldwide. Vivax malaria protein 1 (VMP001), a novel chimeric protein that incorporates the amino- an...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	PLoS neglected tropical diseases 2016-02, Vol.10 (2)
Hauptverfasser:	Bennett, Jason W, Yadava, Anjali, Tosh, Donna, Sattabongkot, Jetsumon, Komisar, Jack, Ware, Lisa A, McCarthy, William F, Cowden, Jessica J, Regules, Jason, Spring, Michele D, Paolino, Kristopher, Hartzell, Joshua D, Cummings, James F, Richie, Thomas L, Lumsden, Joanne, Kamau, Edwin, Murphy, Jittawadee, Lee, Cynthia, Parekh, Falgunee, Birkett, Ashley, Cohen, Joe, Ballou, W Ripley, Polhemus, Mark E, Vanloubbeeck, Yannick F, Vekemans, Johan, Ockenhouse, Christian F
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Copyright Funding Immunization Immunogenicity Immunoglobulins Infections Malaria Parasites Parasitic diseases Proteins Tropical diseases Vaccines Vector-borne diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!